Sentence	entity_1	entity_2	entity_3	entity_4	entity_5	entity_6	entity_7	json	split
PCR primers and conditions for expression analysis of DNMT or MBP ( DNMT1 DNMT3A, DNMT3B, MeCP, MBD1, MBD2 and MBD4) were published elsewhere ( 28).	( DNMT1,66,73,Protein	DNMT3A,74,80,Protein	DNMT3B,82,88,Protein	MeCP,90,94,Protein	MBD1,96,100,Protein	MBD2,102,106,Protein	MBD4,111,115,Protein	"[{""token"": ""( DNMT1"", ""start_span"": 66, ""end_span"": 73, ""type"": ""Protein""}, {""token"": ""DNMT3A"", ""start_span"": 74, ""end_span"": 80, ""type"": ""Protein""}, {""token"": ""DNMT3B"", ""start_span"": 82, ""end_span"": 88, ""type"": ""Protein""}, {""token"": ""MeCP"", ""start_span"": 90, ""end_span"": 94, ""type"": ""Protein""}, {""token"": ""MBD1"", ""start_span"": 96, ""end_span"": 100, ""type"": ""Protein""}, {""token"": ""MBD2"", ""start_span"": 102, ""end_span"": 106, ""type"": ""Protein""}, {""token"": ""MBD4"", ""start_span"": 111, ""end_span"": 115, ""type"": ""Protein""}]"	train
To determine whether Foxp3 functioned by directly signaling through CREB, we utilized expression vectors encoding CREB - 1 or c - Jun ( a member of the activator protein 1 family of transcription factors) fused in - frame to the Gal4 - BD ( Gal4 - BD - CREB - 1 and Gal4 - BD - c - Jun).	Foxp3,21,26,Protein	CREB - 1,114,122,Protein	c - Jun,126,133,Protein	activator protein 1,152,171,Protein	Gal4,229,233,Protein	Gal4 - BD - CREB - 1,241,261,Protein	Gal4 - BD - c - Jun,266,285,Protein	"[{""token"": ""Foxp3"", ""start_span"": 21, ""end_span"": 26, ""type"": ""Protein""}, {""token"": ""CREB - 1"", ""start_span"": 114, ""end_span"": 122, ""type"": ""Protein""}, {""token"": ""c - Jun"", ""start_span"": 126, ""end_span"": 133, ""type"": ""Protein""}, {""token"": ""activator protein 1"", ""start_span"": 152, ""end_span"": 171, ""type"": ""Protein""}, {""token"": ""Gal4"", ""start_span"": 229, ""end_span"": 233, ""type"": ""Protein""}, {""token"": ""Gal4 - BD - CREB - 1"", ""start_span"": 241, ""end_span"": 261, ""type"": ""Protein""}, {""token"": ""Gal4 - BD - c - Jun"", ""start_span"": 266, ""end_span"": 285, ""type"": ""Protein""}]"	train
There was no significant difference in the expression of IL15 and IFNgamma between LMP1 transgenic lymphocytes and lymphoma cells, suggesting that upregulation of IL15 and IFNgamma is induced by LMP1 expression in healthy lymphocytes but is not a unique property of malignant lymphocytes.	IL15,57,61,Protein	IFNgamma,66,74,Protein	LMP1,83,87,Protein	lymphoma cells,115,129,Protein	IL15,163,167,Protein	IFNgamma,172,180,Protein	LMP1,195,199,Protein	"[{""token"": ""IL15"", ""start_span"": 57, ""end_span"": 61, ""type"": ""Protein""}, {""token"": ""IFNgamma"", ""start_span"": 66, ""end_span"": 74, ""type"": ""Protein""}, {""token"": ""LMP1"", ""start_span"": 83, ""end_span"": 87, ""type"": ""Protein""}, {""token"": ""lymphoma cells"", ""start_span"": 115, ""end_span"": 129, ""type"": ""Protein""}, {""token"": ""IL15"", ""start_span"": 163, ""end_span"": 167, ""type"": ""Protein""}, {""token"": ""IFNgamma"", ""start_span"": 172, ""end_span"": 180, ""type"": ""Protein""}, {""token"": ""LMP1"", ""start_span"": 195, ""end_span"": 199, ""type"": ""Protein""}]"	train
Interestingly, both wild - type and LMP1 transgenic lymphomas were similarly susceptible to triciribine, BAY11 - 7085, and cucurbitacin I treatments, but not SB202190, AG490, or U0126 treatment, suggesting that activation of Akt, NFkappaB, and Stat3 but not MAPK pathways are characteristics associated with malignant transformation ( Figure 7). rapamycin, an inhibitor of mTOR, did not affect the viability of the transgenic lymphocytes or lymphoma cells, confirming that mTOR is not targeted by Akt activation in LMP1 transgenic lymphocytes or malignant lymphoma cells ( Figure 7).	LMP1,36,40,Protein	Akt,225,228,Protein	Stat3,244,249,Protein	mTOR,373,377,Protein	mTOR,473,477,Protein	Akt,497,500,Protein	LMP1,515,519,Protein	"[{""token"": ""LMP1"", ""start_span"": 36, ""end_span"": 40, ""type"": ""Protein""}, {""token"": ""Akt"", ""start_span"": 225, ""end_span"": 228, ""type"": ""Protein""}, {""token"": ""Stat3"", ""start_span"": 244, ""end_span"": 249, ""type"": ""Protein""}, {""token"": ""mTOR"", ""start_span"": 373, ""end_span"": 377, ""type"": ""Protein""}, {""token"": ""mTOR"", ""start_span"": 473, ""end_span"": 477, ""type"": ""Protein""}, {""token"": ""Akt"", ""start_span"": 497, ""end_span"": 500, ""type"": ""Protein""}, {""token"": ""LMP1"", ""start_span"": 515, ""end_span"": 519, ""type"": ""Protein""}]"	train
Runx3 bound to the Prf1 and Gzmb transcription start sites ( TSS); to a known IL - 2 responsive enhancer located near - 1 kb of the Prf1 gene ( 23); to the distal CTL - specific DNase I hypersensitive site 9 in the Prf1 locus ( 24); to the Ifng promoter near the TSS, as previously reported for Th1 cells ( 10); and to several DNase I hypersensitive sites in the Ifng locus ( Fig. 3 D and not depicted) ( 25).	Runx3,0,5,Protein	Prf1,19,23,Protein	Gzmb,28,32,Protein	Prf1,132,136,Protein	Prf1,215,219,Protein	Ifng,240,244,Protein	Ifng,363,367,Protein	"[{""token"": ""Runx3"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""Prf1"", ""start_span"": 19, ""end_span"": 23, ""type"": ""Protein""}, {""token"": ""Gzmb"", ""start_span"": 28, ""end_span"": 32, ""type"": ""Protein""}, {""token"": ""Prf1"", ""start_span"": 132, ""end_span"": 136, ""type"": ""Protein""}, {""token"": ""Prf1"", ""start_span"": 215, ""end_span"": 219, ""type"": ""Protein""}, {""token"": ""Ifng"", ""start_span"": 240, ""end_span"": 244, ""type"": ""Protein""}, {""token"": ""Ifng"", ""start_span"": 363, ""end_span"": 367, ""type"": ""Protein""}]"	train
Reconstitution of Runx3 - / - CD8 + T cells with Runx3 restored expression of Eomes as well as perforin, granzyme B, and IFN - gamma ( Fig. 4, A and B).	Runx3,18,23,Protein	CD8,30,33,Protein	Runx3,49,54,Protein	Eomes,78,83,Protein	perforin,95,103,Protein	granzyme B,105,115,Protein	IFN - gamma,121,132,Protein	"[{""token"": ""Runx3"", ""start_span"": 18, ""end_span"": 23, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 30, ""end_span"": 33, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 49, ""end_span"": 54, ""type"": ""Protein""}, {""token"": ""Eomes"", ""start_span"": 78, ""end_span"": 83, ""type"": ""Protein""}, {""token"": ""perforin"", ""start_span"": 95, ""end_span"": 103, ""type"": ""Protein""}, {""token"": ""granzyme B"", ""start_span"": 105, ""end_span"": 115, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 121, ""end_span"": 132, ""type"": ""Protein""}]"	train
The following antibodies used for intracellular or surface stains were obtained from eBioscience: anti - IL - 2, anti - IFN - gamma, anti - TNF, anti - granzyme B, anti - CD8, anti - CD25, and anti - CD44.	IL - 2,105,111,Protein	IFN - gamma,120,131,Protein	TNF,140,143,Protein	granzyme B,152,162,Protein	CD8,171,174,Protein	CD25,183,187,Protein	CD44,200,204,Protein	"[{""token"": ""IL - 2"", ""start_span"": 105, ""end_span"": 111, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 120, ""end_span"": 131, ""type"": ""Protein""}, {""token"": ""TNF"", ""start_span"": 140, ""end_span"": 143, ""type"": ""Protein""}, {""token"": ""granzyme B"", ""start_span"": 152, ""end_span"": 162, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 171, ""end_span"": 174, ""type"": ""Protein""}, {""token"": ""CD25"", ""start_span"": 183, ""end_span"": 187, ""type"": ""Protein""}, {""token"": ""CD44"", ""start_span"": 200, ""end_span"": 204, ""type"": ""Protein""}]"	train
We therefore further fractionated the positively selected CD8 + T cells from Runx3 KO mice into CD8 + CD4 - SP or CD8 + CD4 + DP cells by separation using anti - CD4 magnetic beads.	CD8,58,61,Protein	Runx3,77,82,Protein	CD8,96,99,Protein	CD4,102,105,Protein	CD8,114,117,Protein	CD4,120,123,Protein	CD4,162,165,Protein	"[{""token"": ""CD8"", ""start_span"": 58, ""end_span"": 61, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 77, ""end_span"": 82, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 96, ""end_span"": 99, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 102, ""end_span"": 105, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 114, ""end_span"": 117, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 120, ""end_span"": 123, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 162, ""end_span"": 165, ""type"": ""Protein""}]"	train
( B) Northern blot analysis of Prf1 and GzmB mRNA expression in WT or T - bet - deficient CD8 + T cells activated and either left uninfected ( uninf) or transduced with retroviruses expressing Eomes - VP16 ( Eo - VP16) or an empty IRES - GFP cassette ( GFP).	Prf1,31,35,Protein	GzmB,40,44,Protein	T - bet,70,77,Protein	CD8,90,93,Protein	Eomes - VP16,193,205,Protein	Eo - VP16,208,217,Protein	GFP,238,241,Protein	"[{""token"": ""Prf1"", ""start_span"": 31, ""end_span"": 35, ""type"": ""Protein""}, {""token"": ""GzmB"", ""start_span"": 40, ""end_span"": 44, ""type"": ""Protein""}, {""token"": ""T - bet"", ""start_span"": 70, ""end_span"": 77, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 90, ""end_span"": 93, ""type"": ""Protein""}, {""token"": ""Eomes - VP16"", ""start_span"": 193, ""end_span"": 205, ""type"": ""Protein""}, {""token"": ""Eo - VP16"", ""start_span"": 208, ""end_span"": 217, ""type"": ""Protein""}, {""token"": ""GFP"", ""start_span"": 238, ""end_span"": 241, ""type"": ""Protein""}]"	train
( A) Western analysis of Runx3, Eomes, T - bet, and perforin expression in Runx3 + / + versus Runx3 - / - CD8 + SP T cells differentiated for 6 d.	Runx3,25,30,Protein	Eomes,32,37,Protein	T - bet,39,46,Protein	perforin,52,60,Protein	Runx3,75,80,Protein	Runx3,94,99,Protein	CD8,106,109,Protein	"[{""token"": ""Runx3"", ""start_span"": 25, ""end_span"": 30, ""type"": ""Protein""}, {""token"": ""Eomes"", ""start_span"": 32, ""end_span"": 37, ""type"": ""Protein""}, {""token"": ""T - bet"", ""start_span"": 39, ""end_span"": 46, ""type"": ""Protein""}, {""token"": ""perforin"", ""start_span"": 52, ""end_span"": 60, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 75, ""end_span"": 80, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 94, ""end_span"": 99, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 106, ""end_span"": 109, ""type"": ""Protein""}]"	train
( C) Expression of granzyme B, IFN - gamma, TNF, and IL - 2 by resting or restimulated ( 6 h) Runx3 + / + versus Runx3 - / - CD8 + SP T cells differentiated for 6 d.	granzyme B,19,29,Protein	IFN - gamma,31,42,Protein	TNF,44,47,Protein	IL - 2,53,59,Protein	Runx3,94,99,Protein	Runx3,113,118,Protein	CD8,125,128,Protein	"[{""token"": ""granzyme B"", ""start_span"": 19, ""end_span"": 29, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 31, ""end_span"": 42, ""type"": ""Protein""}, {""token"": ""TNF"", ""start_span"": 44, ""end_span"": 47, ""type"": ""Protein""}, {""token"": ""IL - 2"", ""start_span"": 53, ""end_span"": 59, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 94, ""end_span"": 99, ""type"": ""Protein""}, {""token"": ""Runx3"", ""start_span"": 113, ""end_span"": 118, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 125, ""end_span"": 128, ""type"": ""Protein""}]"	train
Runx3 is present in naive CD8 + T cells and represses Runx1 and induces Eomes, perforin, granzyme B, and IFN - gamma expression.	Runx3,0,5,Protein	CD8,26,29,Protein	Runx1,54,59,Protein	Eomes,72,77,Protein	perforin,79,87,Protein	granzyme B,89,99,Protein	IFN - gamma,105,116,Protein	"[{""token"": ""Runx3"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 26, ""end_span"": 29, ""type"": ""Protein""}, {""token"": ""Runx1"", ""start_span"": 54, ""end_span"": 59, ""type"": ""Protein""}, {""token"": ""Eomes"", ""start_span"": 72, ""end_span"": 77, ""type"": ""Protein""}, {""token"": ""perforin"", ""start_span"": 79, ""end_span"": 87, ""type"": ""Protein""}, {""token"": ""granzyme B"", ""start_span"": 89, ""end_span"": 99, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 105, ""end_span"": 116, ""type"": ""Protein""}]"	train
In vitro human CD4 + and CD8 + T cell clones, or mouse CD4 + T cells that produce both interferon - gamma ( IFN - gamma) and IL - 10, can be differentiated by T cell receptor ( TCR) - stimulation in the presence of IL - 12 ( Chang et al., 2007; Gerosa et al., 1996; Jeannin et al., 1996; Meyaard et al., 1996; Windhagen et al., 1996).	CD4,15,18,Protein	CD8,25,28,Protein	CD4,55,58,Protein	interferon - gamma,87,105,Protein	IFN - gamma,108,119,Protein	IL - 10,125,132,Protein	IL - 12,215,222,Protein	"[{""token"": ""CD4"", ""start_span"": 15, ""end_span"": 18, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 25, ""end_span"": 28, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 55, ""end_span"": 58, ""type"": ""Protein""}, {""token"": ""interferon - gamma"", ""start_span"": 87, ""end_span"": 105, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 108, ""end_span"": 119, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 125, ""end_span"": 132, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 215, ""end_span"": 222, ""type"": ""Protein""}]"	train
Culture of naive CD4 + T cells in an APC - free system by stimulation with anti - CD3 and anti - CD28 antibodies in the presence of IL - 12 resulted in IFN - gamma - producing Th1 cells, a proportion of which coproduced IL - 10, as did Th2 cells resulting from culture in IL - 4 ( Figure S1B).	CD4,17,20,Protein	CD3,82,85,Protein	CD28,97,101,Protein	IL - 12,132,139,Protein	IFN - gamma,152,163,Protein	IL - 10,220,227,Protein	IL - 4,272,278,Protein	"[{""token"": ""CD4"", ""start_span"": 17, ""end_span"": 20, ""type"": ""Protein""}, {""token"": ""CD3"", ""start_span"": 82, ""end_span"": 85, ""type"": ""Protein""}, {""token"": ""CD28"", ""start_span"": 97, ""end_span"": 101, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 132, ""end_span"": 139, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 152, ""end_span"": 163, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 220, ""end_span"": 227, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 272, ""end_span"": 278, ""type"": ""Protein""}]"	train
To investigate whether the inability of STAT4 - deficient T cells to produce IL - 10 might be due to the absence of IFN - gamma, as suggested before ( Shaw et al., 2006), we differentiated DO11. 10 or DO11. 10 IFN - gamma - deficient naive CD4 + T cells in the presence of IL - 12 and increasing doses of OVA.	STAT4,40,45,Protein	IL - 10,77,84,Protein	IFN - gamma,116,127,Protein	IFN - gamma,210,221,Protein	CD4,240,243,Protein	IL - 12,273,280,Protein	OVA,305,308,Protein	"[{""token"": ""STAT4"", ""start_span"": 40, ""end_span"": 45, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 77, ""end_span"": 84, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 116, ""end_span"": 127, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 210, ""end_span"": 221, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 240, ""end_span"": 243, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 273, ""end_span"": 280, ""type"": ""Protein""}, {""token"": ""OVA"", ""start_span"": 305, ""end_span"": 308, ""type"": ""Protein""}]"	train
Th1 cells induced in the first week to produce IL - 10 by culture with high antigen doses and IL - 12 lost their ability to express IL - 10 when recultured with low doses of OVA, which could be compensated for, to some extent, by addition of IL - 12 to the secondary cultures ( Figure 4F), again suggesting that antigen dose and IL - 12 signals cooperate for the induction of IL - 10.	IL - 10,47,54,Protein	IL - 12,94,101,Protein	IL - 10,132,139,Protein	OVA,174,177,Protein	IL - 12,242,249,Protein	IL - 12,329,336,Protein	IL - 10,376,383,Protein	"[{""token"": ""IL - 10"", ""start_span"": 47, ""end_span"": 54, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 94, ""end_span"": 101, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 132, ""end_span"": 139, ""type"": ""Protein""}, {""token"": ""OVA"", ""start_span"": 174, ""end_span"": 177, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 242, ""end_span"": 249, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 329, ""end_span"": 336, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 376, ""end_span"": 383, ""type"": ""Protein""}]"	train
It has also been shown that maintenance of IL - 10 expression is conditional on IL - 12 or IL - 4 unless the IL - 10 gene is imprinted by GATA - 3 ( Chang et al., 2007), which can remodel the IL - 10 locus, thus explaining the highest amounts of IL - 10 produced by Th2 cells ( Chang et al., 2007; Shoemaker et al., 2006).	IL - 10,43,50,Protein	IL - 12,80,87,Protein	IL - 4,91,97,Protein	IL - 10,109,116,Protein	GATA - 3,138,146,Protein	IL - 10,192,199,Protein	IL - 10,246,253,Protein	"[{""token"": ""IL - 10"", ""start_span"": 43, ""end_span"": 50, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 80, ""end_span"": 87, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 91, ""end_span"": 97, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 109, ""end_span"": 116, ""type"": ""Protein""}, {""token"": ""GATA - 3"", ""start_span"": 138, ""end_span"": 146, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 192, ""end_span"": 199, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 246, ""end_span"": 253, ""type"": ""Protein""}]"	train
The amounts of TRAF2, TRAF3, and cIAP1 in CD40 immunoprecipitates from HOIP - deficient cells were similar to those from parental A20. 2J cells, indicating that HOIP is not required for the association of these proteins with CD40.	TRAF2,15,20,Protein	TRAF3,22,27,Protein	cIAP1,33,38,Protein	CD40,42,46,Protein	HOIP,71,75,Protein	HOIP,161,165,Protein	CD40,225,229,Protein	"[{""token"": ""TRAF2"", ""start_span"": 15, ""end_span"": 20, ""type"": ""Protein""}, {""token"": ""TRAF3"", ""start_span"": 22, ""end_span"": 27, ""type"": ""Protein""}, {""token"": ""cIAP1"", ""start_span"": 33, ""end_span"": 38, ""type"": ""Protein""}, {""token"": ""CD40"", ""start_span"": 42, ""end_span"": 46, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 71, ""end_span"": 75, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 161, ""end_span"": 165, ""type"": ""Protein""}, {""token"": ""CD40"", ""start_span"": 225, ""end_span"": 229, ""type"": ""Protein""}]"	train
A20. 2J and HOIP - deficient cells transduced with an empty retroviral vector ( A20. 2J + pMIP and HOIP - / - + pMIP, respectively), or HOIP - deficient cells transduced with a HOIP - encoding retrovirus ( HOIP - / - + HOIP) were cultured overnight with agonistic anti - CD40 or an isotype control antibody ( iso), with or without IL - 4.	HOIP,12,16,Protein	HOIP,99,103,Protein	HOIP,136,140,Protein	HOIP,177,181,Protein	HOIP,206,210,Protein	HOIP,219,223,Protein	IL - 4,331,337,Protein	"[{""token"": ""HOIP"", ""start_span"": 12, ""end_span"": 16, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 99, ""end_span"": 103, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 136, ""end_span"": 140, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 177, ""end_span"": 181, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 206, ""end_span"": 210, ""type"": ""Protein""}, {""token"": ""HOIP"", ""start_span"": 219, ""end_span"": 223, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 331, ""end_span"": 337, ""type"": ""Protein""}]"	train
To determine if the Sharpin mutation affects DC development in lymphoid tissues, mouse spleens were examined for the distribution of conventional DC ( cDC; CD11c + CD8alpha + and CD11c + CD8alpha -) [ 13] and plasmacytoid DC ( pDC; CD11c - PDCA - 1 +) [ 14].	Sharpin,20,27,Protein	CD11c,156,161,Protein	CD8alpha,164,172,Protein	CD11c,179,184,Protein	CD8alpha,187,195,Protein	CD11c,232,237,Protein	PDCA - 1,240,248,Protein	"[{""token"": ""Sharpin"", ""start_span"": 20, ""end_span"": 27, ""type"": ""Protein""}, {""token"": ""CD11c"", ""start_span"": 156, ""end_span"": 161, ""type"": ""Protein""}, {""token"": ""CD8alpha"", ""start_span"": 164, ""end_span"": 172, ""type"": ""Protein""}, {""token"": ""CD11c"", ""start_span"": 179, ""end_span"": 184, ""type"": ""Protein""}, {""token"": ""CD8alpha"", ""start_span"": 187, ""end_span"": 195, ""type"": ""Protein""}, {""token"": ""CD11c"", ""start_span"": 232, ""end_span"": 237, ""type"": ""Protein""}, {""token"": ""PDCA - 1"", ""start_span"": 240, ""end_span"": 248, ""type"": ""Protein""}]"	train
The following reagents were used at indicated concentrations: recombinant human ( rhu) BMP - 6 ( 1 mug / ml, if not specified otherwise), rhu BMP - RIB / ALK - 6 / Fc Chimera ( 5 mug / ml), rhu BMPR - II / Fc Chimera ( 5 mug / ml), and recombinant mouse Noggin ( 5 mug / ml) were purchased from R & D Systems ( Abingdon, UK); Anti - IgM F ( ab) 2 fragments of rabbit polyclonal antibodies to human IgM heavy chain ( 37. 5 mug / ml) was obtained from Dako, Copenhagen, Denmark and rhu CD40 ligand ( CD40L, 10 ng / ml) was a gift from Immunex Corp.	BMP - 6,87,94,Protein	BMP - RIB,142,151,Protein	ALK - 6,154,161,Protein	BMPR - II,194,203,Protein	Noggin,254,260,Protein	CD40 ligand,484,495,Protein	CD40L,498,503,Protein	"[{""token"": ""BMP - 6"", ""start_span"": 87, ""end_span"": 94, ""type"": ""Protein""}, {""token"": ""BMP - RIB"", ""start_span"": 142, ""end_span"": 151, ""type"": ""Protein""}, {""token"": ""ALK - 6"", ""start_span"": 154, ""end_span"": 161, ""type"": ""Protein""}, {""token"": ""BMPR - II"", ""start_span"": 194, ""end_span"": 203, ""type"": ""Protein""}, {""token"": ""Noggin"", ""start_span"": 254, ""end_span"": 260, ""type"": ""Protein""}, {""token"": ""CD40 ligand"", ""start_span"": 484, ""end_span"": 495, ""type"": ""Protein""}, {""token"": ""CD40L"", ""start_span"": 498, ""end_span"": 503, ""type"": ""Protein""}]"	valid
Highly purified CD19 + CD27 - or CD19 + CD27 + cells were obtained by staining CD19 + cells with anti - CD27 PE and CD19 PC5 mAbs for 30 minutes at 4degreesC, followed by washing with PBS and sorting on FACS DiVa from Becton Dickinson.	CD19,16,20,Protein	CD27,23,27,Protein	CD19,33,37,Protein	CD27,40,44,Protein	CD19,79,83,Protein	CD27,104,108,Protein	CD19,116,120,Protein	"[{""token"": ""CD19"", ""start_span"": 16, ""end_span"": 20, ""type"": ""Protein""}, {""token"": ""CD27"", ""start_span"": 23, ""end_span"": 27, ""type"": ""Protein""}, {""token"": ""CD19"", ""start_span"": 33, ""end_span"": 37, ""type"": ""Protein""}, {""token"": ""CD27"", ""start_span"": 40, ""end_span"": 44, ""type"": ""Protein""}, {""token"": ""CD19"", ""start_span"": 79, ""end_span"": 83, ""type"": ""Protein""}, {""token"": ""CD27"", ""start_span"": 104, ""end_span"": 108, ""type"": ""Protein""}, {""token"": ""CD19"", ""start_span"": 116, ""end_span"": 120, ""type"": ""Protein""}]"	valid
In primates, the seven paralogs APOBEC3A, B, C, DE, F, G, H ( A3A - H) have been described ( 3), and they appear to fulfill individual functions.	APOBEC3A,32,40,Protein	B,42,43,Protein	C,45,46,Protein	DE,48,50,Protein	F,52,53,Protein	G,55,56,Protein	H,58,59,Protein	"[{""token"": ""APOBEC3A"", ""start_span"": 32, ""end_span"": 40, ""type"": ""Protein""}, {""token"": ""B"", ""start_span"": 42, ""end_span"": 43, ""type"": ""Protein""}, {""token"": ""C"", ""start_span"": 45, ""end_span"": 46, ""type"": ""Protein""}, {""token"": ""DE"", ""start_span"": 48, ""end_span"": 50, ""type"": ""Protein""}, {""token"": ""F"", ""start_span"": 52, ""end_span"": 53, ""type"": ""Protein""}, {""token"": ""G"", ""start_span"": 55, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""H"", ""start_span"": 58, ""end_span"": 59, ""type"": ""Protein""}]"	valid
This mutation increased luciferase activity by 3 - fold in memory CD4 + CD45RO + T cells, whereas no difference was observed in naive ( GATA3 -) CD4 + CD45RA + T cells, revealing a repressor activity of GATA3 on the FOXP3 promoter ( Figure 8C).	CD4,66,69,Protein	CD45RO,72,78,Protein	GATA3,136,141,Protein	CD4,145,148,Protein	CD45RA,151,157,Protein	GATA3,203,208,Protein	FOXP3,216,221,Protein	"[{""token"": ""CD4"", ""start_span"": 66, ""end_span"": 69, ""type"": ""Protein""}, {""token"": ""CD45RO"", ""start_span"": 72, ""end_span"": 78, ""type"": ""Protein""}, {""token"": ""GATA3"", ""start_span"": 136, ""end_span"": 141, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 145, ""end_span"": 148, ""type"": ""Protein""}, {""token"": ""CD45RA"", ""start_span"": 151, ""end_span"": 157, ""type"": ""Protein""}, {""token"": ""GATA3"", ""start_span"": 203, ""end_span"": 208, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 216, ""end_span"": 221, ""type"": ""Protein""}]"	valid
In contrast, differentiating naive T cells in the absence of polarization factors ( Th0) such as IL - 4, IL - 12, or TGF - beta showed only a transient FOXP3 expression and failed to generate a population of FOXP3 - expressing cells, but GATA3 and T - bet were up - regulated ( unpublished data).	IL - 4,97,103,Protein	IL - 12,105,112,Protein	TGF - beta,117,127,Protein	FOXP3,152,157,Protein	FOXP3,208,213,Protein	GATA3,238,243,Protein	T - bet,248,255,Protein	"[{""token"": ""IL - 4"", ""start_span"": 97, ""end_span"": 103, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 105, ""end_span"": 112, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 117, ""end_span"": 127, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 152, ""end_span"": 157, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 208, ""end_span"": 213, ""type"": ""Protein""}, {""token"": ""GATA3"", ""start_span"": 238, ""end_span"": 243, ""type"": ""Protein""}, {""token"": ""T - bet"", ""start_span"": 248, ""end_span"": 255, ""type"": ""Protein""}]"	valid
Here, naive CD4 + T cells were cultured with IL - 2, anti - CD2 / 3 / 28 mAb, and TGF - beta as a Foxp3 - inducing stimulation.	CD4,12,15,Protein	IL - 2,45,51,Protein	CD2,60,63,Protein	3,66,67,Protein	28,70,72,Protein	TGF - beta,82,92,Protein	Foxp3,98,103,Protein	"[{""token"": ""CD4"", ""start_span"": 12, ""end_span"": 15, ""type"": ""Protein""}, {""token"": ""IL - 2"", ""start_span"": 45, ""end_span"": 51, ""type"": ""Protein""}, {""token"": ""CD2"", ""start_span"": 60, ""end_span"": 63, ""type"": ""Protein""}, {""token"": ""3"", ""start_span"": 66, ""end_span"": 67, ""type"": ""Protein""}, {""token"": ""28"", ""start_span"": 70, ""end_span"": 72, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 82, ""end_span"": 92, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 98, ""end_span"": 103, ""type"": ""Protein""}]"	valid
To investigate the effect of RUNX1 and RUNX3 binding to the RUNX binding sites in the FOXP3 promoter, we transfected human peripheral blood CD4 + T cells with a FOXP3 promoter luciferase reporter vector and RUNX1 or RUNX3 expression vectors.	RUNX1,29,34,Protein	RUNX3,39,44,Protein	FOXP3,86,91,Protein	CD4,140,143,Protein	FOXP3 promoter luciferase,161,186,Protein	RUNX1,207,212,Protein	RUNX3,216,221,Protein	"[{""token"": ""RUNX1"", ""start_span"": 29, ""end_span"": 34, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 39, ""end_span"": 44, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 86, ""end_span"": 91, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 140, ""end_span"": 143, ""type"": ""Protein""}, {""token"": ""FOXP3 promoter luciferase"", ""start_span"": 161, ""end_span"": 186, ""type"": ""Protein""}, {""token"": ""RUNX1"", ""start_span"": 207, ""end_span"": 212, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 216, ""end_span"": 221, ""type"": ""Protein""}]"	valid
Retinoic acid enhanced Foxp3 expression even in 20 pg / ml of TGF - beta and more than 95% of the CD4 + T cells from CbfbF / + CD4 - cre mice became Foxp3 + in 100 and 500 pg / ml TGF - beta doses.	Foxp3,23,28,Protein	TGF - beta,62,72,Protein	CD4,98,101,Protein	CbfbF,117,122,Protein	CD4 - cre,127,136,Protein	Foxp3,149,154,Protein	TGF - beta,180,190,Protein	"[{""token"": ""Foxp3"", ""start_span"": 23, ""end_span"": 28, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 62, ""end_span"": 72, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 98, ""end_span"": 101, ""type"": ""Protein""}, {""token"": ""CbfbF"", ""start_span"": 117, ""end_span"": 122, ""type"": ""Protein""}, {""token"": ""CD4 - cre"", ""start_span"": 127, ""end_span"": 136, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 149, ""end_span"": 154, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 180, ""end_span"": 190, ""type"": ""Protein""}]"	valid
The induction of Foxp3 was again significantly lower in CbfbF / F CD4 - cre CD4 + T cells even in the presence of retinoic acid, demonstrating that deficiency in Runx binding to DNA affects the TGF - beta induction of Foxp3 in T reg cells ( Fig. 5 A).	Foxp3,17,22,Protein	CbfbF,56,61,Protein	CD4 - cre,66,75,Protein	CD4,76,79,Protein	Runx,162,166,Protein	TGF - beta,194,204,Protein	Foxp3,218,223,Protein	"[{""token"": ""Foxp3"", ""start_span"": 17, ""end_span"": 22, ""type"": ""Protein""}, {""token"": ""CbfbF"", ""start_span"": 56, ""end_span"": 61, ""type"": ""Protein""}, {""token"": ""CD4 - cre"", ""start_span"": 66, ""end_span"": 75, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 76, ""end_span"": 79, ""type"": ""Protein""}, {""token"": ""Runx"", ""start_span"": 162, ""end_span"": 166, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 194, ""end_span"": 204, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 218, ""end_span"": 223, ""type"": ""Protein""}]"	valid
Even though Cbfb - deficient CD4 + T cells had impaired induction of Foxp3 after stimulation with anti - CD3 / 28 mAbs and TGF - beta, sufficient numbers of Foxp3 + cells could be generated to permit analysis of their suppressive activity.	Cbfb,12,16,Protein	CD4,29,32,Protein	Foxp3,69,74,Protein	CD3,105,108,Protein	28,111,113,Protein	TGF - beta,123,133,Protein	Foxp3,157,162,Protein	"[{""token"": ""Cbfb"", ""start_span"": 12, ""end_span"": 16, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 29, ""end_span"": 32, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 69, ""end_span"": 74, ""type"": ""Protein""}, {""token"": ""CD3"", ""start_span"": 105, ""end_span"": 108, ""type"": ""Protein""}, {""token"": ""28"", ""start_span"": 111, ""end_span"": 113, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 123, ""end_span"": 133, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 157, ""end_span"": 162, ""type"": ""Protein""}]"	valid
Foxp3 induction by TGF - beta is reduced in CD4 + T cells of CbfbF / F CD4 - cre mice compared with CbfbF / + CD4 - cre mice.	Foxp3,0,5,Protein	TGF - beta,19,29,Protein	CD4,44,47,Protein	CbfbF,61,66,Protein	CD4 - cre,71,80,Protein	CbfbF,100,105,Protein	CD4 - cre,110,119,Protein	"[{""token"": ""Foxp3"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 19, ""end_span"": 29, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 44, ""end_span"": 47, ""type"": ""Protein""}, {""token"": ""CbfbF"", ""start_span"": 61, ""end_span"": 66, ""type"": ""Protein""}, {""token"": ""CD4 - cre"", ""start_span"": 71, ""end_span"": 80, ""type"": ""Protein""}, {""token"": ""CbfbF"", ""start_span"": 100, ""end_span"": 105, ""type"": ""Protein""}, {""token"": ""CD4 - cre"", ""start_span"": 110, ""end_span"": 119, ""type"": ""Protein""}]"	valid
We observed an increased number of Foxp3 + cells by retinoic acid and TGF - beta compared with TGF - beta treatment alone in CbfbF / + CD4 - cre mice and CbfbF / F CD4 - cre mice.	Foxp3,35,40,Protein	TGF - beta,70,80,Protein	TGF - beta,95,105,Protein	CbfbF,125,130,Protein	CD4 - cre,135,144,Protein	CbfbF,154,159,Protein	CD4 - cre,164,173,Protein	"[{""token"": ""Foxp3"", ""start_span"": 35, ""end_span"": 40, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 70, ""end_span"": 80, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 95, ""end_span"": 105, ""type"": ""Protein""}, {""token"": ""CbfbF"", ""start_span"": 125, ""end_span"": 130, ""type"": ""Protein""}, {""token"": ""CD4 - cre"", ""start_span"": 135, ""end_span"": 144, ""type"": ""Protein""}, {""token"": ""CbfbF"", ""start_span"": 154, ""end_span"": 159, ""type"": ""Protein""}, {""token"": ""CD4 - cre"", ""start_span"": 164, ""end_span"": 173, ""type"": ""Protein""}]"	valid
For Th17 conditions, cells were stimulated with the following: 40 ng / ml IL - 2, 20 ng / ml IL - 6, 5 ng / ml TGF - beta, 20 ng / ml IL - 23 ( Alexis Biochemicals Corp.), 10 ng / ml IL - 1beta, 5 microg / ml anti - IL - 4, and 5 microg / ml anti - IL - 12 were used.	IL - 2,74,80,Protein	IL - 6,93,99,Protein	TGF - beta,111,121,Protein	IL - 23,134,141,Protein	IL - 1beta,183,193,Protein	IL - 4,216,222,Protein	IL - 12,249,256,Protein	"[{""token"": ""IL - 2"", ""start_span"": 74, ""end_span"": 80, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 93, ""end_span"": 99, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 111, ""end_span"": 121, ""type"": ""Protein""}, {""token"": ""IL - 23"", ""start_span"": 134, ""end_span"": 141, ""type"": ""Protein""}, {""token"": ""IL - 1beta"", ""start_span"": 183, ""end_span"": 193, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 216, ""end_span"": 222, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 249, ""end_span"": 256, ""type"": ""Protein""}]"	valid
Mouse Foxp3 + CD4 + CD8 - T cells were FACS purified based on GFP expressed from a Foxp3 - IRES - GFP knock - in allele ( Foxp3GFP).	Foxp3,6,11,Protein	CD4,14,17,Protein	CD8,20,23,Protein	GFP,62,65,Protein	Foxp3,83,88,Protein	GFP,98,101,Protein	Foxp3GFP,122,130,Protein	"[{""token"": ""Foxp3"", ""start_span"": 6, ""end_span"": 11, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 14, ""end_span"": 17, ""type"": ""Protein""}, {""token"": ""CD8"", ""start_span"": 20, ""end_span"": 23, ""type"": ""Protein""}, {""token"": ""GFP"", ""start_span"": 62, ""end_span"": 65, ""type"": ""Protein""}, {""token"": ""Foxp3"", ""start_span"": 83, ""end_span"": 88, ""type"": ""Protein""}, {""token"": ""GFP"", ""start_span"": 98, ""end_span"": 101, ""type"": ""Protein""}, {""token"": ""Foxp3GFP"", ""start_span"": 122, ""end_span"": 130, ""type"": ""Protein""}]"	valid
Human naive CD4 + T cells were cultured either with IL - 2 only or with IL - 2, anti - CD2 / 3 / 28, and TGF - beta for 72 h, and protein - DNA complexes were fixed by cross - linking with formaldehyde in a final concentration of 1. 42% for 15 min.	CD4,12,15,Protein	IL - 2,52,58,Protein	IL - 2,72,78,Protein	CD2,87,90,Protein	3,93,94,Protein	28,97,99,Protein	TGF - beta,105,115,Protein	"[{""token"": ""CD4"", ""start_span"": 12, ""end_span"": 15, ""type"": ""Protein""}, {""token"": ""IL - 2"", ""start_span"": 52, ""end_span"": 58, ""type"": ""Protein""}, {""token"": ""IL - 2"", ""start_span"": 72, ""end_span"": 78, ""type"": ""Protein""}, {""token"": ""CD2"", ""start_span"": 87, ""end_span"": 90, ""type"": ""Protein""}, {""token"": ""3"", ""start_span"": 93, ""end_span"": 94, ""type"": ""Protein""}, {""token"": ""28"", ""start_span"": 97, ""end_span"": 99, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 105, ""end_span"": 115, ""type"": ""Protein""}]"	valid
IL - 4, IL - 5, IL - 6, IL - 10, IL - 13, IL - 17, and IFN - gamma secretion was assessed using fluorescent bead - based technology.	IL - 4,0,6,Protein	IL - 5,8,14,Protein	IL - 6,16,22,Protein	IL - 10,24,31,Protein	IL - 13,33,40,Protein	IL - 17,42,49,Protein	IFN - gamma,55,66,Protein	"[{""token"": ""IL - 4"", ""start_span"": 0, ""end_span"": 6, ""type"": ""Protein""}, {""token"": ""IL - 5"", ""start_span"": 8, ""end_span"": 14, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 16, ""end_span"": 22, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 24, ""end_span"": 31, ""type"": ""Protein""}, {""token"": ""IL - 13"", ""start_span"": 33, ""end_span"": 40, ""type"": ""Protein""}, {""token"": ""IL - 17"", ""start_span"": 42, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 55, ""end_span"": 66, ""type"": ""Protein""}]"	valid
( A) Human primary CD4 + cells were transfected with an empty vector ( pGL3 Basic), a vector containing the wild - type or mutated FOXP3 promoter region ( FOXP3 - 511 / + 176) fused to the luciferase reporter gene together with a GFP, RUNX1, or RUNX3 expression vector.	CD4,19,22,Protein	FOXP3,131,136,Protein	FOXP3,155,160,Protein	luciferase,189,199,Protein	GFP,230,233,Protein	RUNX1,235,240,Protein	RUNX3,245,250,Protein	"[{""token"": ""CD4"", ""start_span"": 19, ""end_span"": 22, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 131, ""end_span"": 136, ""type"": ""Protein""}, {""token"": ""FOXP3"", ""start_span"": 155, ""end_span"": 160, ""type"": ""Protein""}, {""token"": ""luciferase"", ""start_span"": 189, ""end_span"": 199, ""type"": ""Protein""}, {""token"": ""GFP"", ""start_span"": 230, ""end_span"": 233, ""type"": ""Protein""}, {""token"": ""RUNX1"", ""start_span"": 235, ""end_span"": 240, ""type"": ""Protein""}, {""token"": ""RUNX3"", ""start_span"": 245, ""end_span"": 250, ""type"": ""Protein""}]"	valid
Since IkappaBalpha degradation is a prerequisite to unmask the NLS of p65, and both RPS3 and IkappaBalpha bind to p65 in the cytoplasmic inhibitory complex, we tested whether IkappaBalpha degradation is required for the liberation of RPS3.	IkappaBalpha,6,18,Protein	p65,70,73,Protein	RPS3,84,88,Protein	IkappaBalpha,93,105,Protein	p65,114,117,Protein	IkappaBalpha,175,187,Protein	RPS3,234,238,Protein	"[{""token"": ""IkappaBalpha"", ""start_span"": 6, ""end_span"": 18, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 70, ""end_span"": 73, ""type"": ""Protein""}, {""token"": ""RPS3"", ""start_span"": 84, ""end_span"": 88, ""type"": ""Protein""}, {""token"": ""IkappaBalpha"", ""start_span"": 93, ""end_span"": 105, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 114, ""end_span"": 117, ""type"": ""Protein""}, {""token"": ""IkappaBalpha"", ""start_span"": 175, ""end_span"": 187, ""type"": ""Protein""}, {""token"": ""RPS3"", ""start_span"": 234, ""end_span"": 238, ""type"": ""Protein""}]"	valid
By in vitro kinase assays using recombinant IKK and RPS3 proteins, we observed strong incorporation of 32P in autophosphorylatd IKKalpha and IKKbeta ( Fig. 4a, lanes 2 - 7) as well as phosporylated GST - IkappaBalpha ( 1 - 54) ( Supplementary Fig. 4), but not the GST protein alone ( Fig. 4a, lanes 3 and 6), when either IKKalpha or IKKbeta was used.	RPS3,52,56,Protein	IKKalpha,128,136,Protein	IKKbeta,141,148,Protein	GST - IkappaBalpha,198,216,Protein	GST,264,267,Protein	IKKalpha,321,329,Protein	IKKbeta,333,340,Protein	"[{""token"": ""RPS3"", ""start_span"": 52, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""IKKalpha"", ""start_span"": 128, ""end_span"": 136, ""type"": ""Protein""}, {""token"": ""IKKbeta"", ""start_span"": 141, ""end_span"": 148, ""type"": ""Protein""}, {""token"": ""GST - IkappaBalpha"", ""start_span"": 198, ""end_span"": 216, ""type"": ""Protein""}, {""token"": ""GST"", ""start_span"": 264, ""end_span"": 267, ""type"": ""Protein""}, {""token"": ""IKKalpha"", ""start_span"": 321, ""end_span"": 329, ""type"": ""Protein""}, {""token"": ""IKKbeta"", ""start_span"": 333, ""end_span"": 340, ""type"": ""Protein""}]"	valid
In HIV - 1 - infected U937 cells, the endogenous Tat was coimmunoprecipitated with IkappaB - alpha and p65 ( Figure 6E), and activated the MIP - 1alpha expression in a p65 - dependent manner, as shown by the lack of effect following RNA interference of Tat or p65 ( Figure 6F).	Tat,49,52,Protein	IkappaB - alpha,83,98,Protein	p65,103,106,Protein	MIP - 1alpha,139,151,Protein	p65,168,171,Protein	Tat,253,256,Protein	p65,260,263,Protein	"[{""token"": ""Tat"", ""start_span"": 49, ""end_span"": 52, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 83, ""end_span"": 98, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 103, ""end_span"": 106, ""type"": ""Protein""}, {""token"": ""MIP - 1alpha"", ""start_span"": 139, ""end_span"": 151, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 168, ""end_span"": 171, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 253, ""end_span"": 256, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 260, ""end_span"": 263, ""type"": ""Protein""}]"	valid
Altogether these results indicated that in single round HIV - 1 infection Tat associated with IkappaB - alpha and p65, and induced the p65 - dependent activation of MIP - 1alpha expression through occupancy of the MIP - 1alpha promoter and increased recruitment of p65.	Tat,74,77,Protein	IkappaB - alpha,94,109,Protein	p65,114,117,Protein	p65,135,138,Protein	MIP - 1alpha,165,177,Protein	MIP - 1alpha,214,226,Protein	p65,265,268,Protein	"[{""token"": ""Tat"", ""start_span"": 74, ""end_span"": 77, ""type"": ""Protein""}, {""token"": ""IkappaB - alpha"", ""start_span"": 94, ""end_span"": 109, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 114, ""end_span"": 117, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 135, ""end_span"": 138, ""type"": ""Protein""}, {""token"": ""MIP - 1alpha"", ""start_span"": 165, ""end_span"": 177, ""type"": ""Protein""}, {""token"": ""MIP - 1alpha"", ""start_span"": 214, ""end_span"": 226, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 265, ""end_span"": 268, ""type"": ""Protein""}]"	valid
( E) p50 - / - p65 - / - MEFs ( 3 x 105 cells) were transfected with pkappaBLuc ( 0. 5 microg) and pSV - beta - Gal ( 0. 1 microg) with or without pRc / CMV - p65 ( 0. 5 microg), pCMV4 - HA - IkappaB - alpha ( 0. 5 microg), p3xFLAG - Tat or p3xFLAG - Tat R ( 49 - 57) A ( 0. 5, 1 and 2 microg).	p50,5,8,Protein	p65,15,18,Protein	beta - Gal,105,115,Protein	p65,159,162,Protein	HA - IkappaB - alpha,187,207,Protein	Tat,234,237,Protein	Tat,251,254,Protein	"[{""token"": ""p50"", ""start_span"": 5, ""end_span"": 8, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 15, ""end_span"": 18, ""type"": ""Protein""}, {""token"": ""beta - Gal"", ""start_span"": 105, ""end_span"": 115, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 159, ""end_span"": 162, ""type"": ""Protein""}, {""token"": ""HA - IkappaB - alpha"", ""start_span"": 187, ""end_span"": 207, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 234, ""end_span"": 237, ""type"": ""Protein""}, {""token"": ""Tat"", ""start_span"": 251, ""end_span"": 254, ""type"": ""Protein""}]"	valid
Twenty - four - hour post - transfection, total RNA was extracted and analysed by real - time PCR to evaluate the expression of MIP - 1alpha ( A), CSF3 ( B), LTA ( C), NFKBIA ( D), TLR2 ( E), GAPDH ( F), ACTB ( G) genes.	MIP - 1alpha,128,140,Protein	CSF3,147,151,Protein	LTA,158,161,Protein	NFKBIA,168,174,Protein	TLR2,181,185,Protein	GAPDH,192,197,Protein	ACTB,204,208,Protein	"[{""token"": ""MIP - 1alpha"", ""start_span"": 128, ""end_span"": 140, ""type"": ""Protein""}, {""token"": ""CSF3"", ""start_span"": 147, ""end_span"": 151, ""type"": ""Protein""}, {""token"": ""LTA"", ""start_span"": 158, ""end_span"": 161, ""type"": ""Protein""}, {""token"": ""NFKBIA"", ""start_span"": 168, ""end_span"": 174, ""type"": ""Protein""}, {""token"": ""TLR2"", ""start_span"": 181, ""end_span"": 185, ""type"": ""Protein""}, {""token"": ""GAPDH"", ""start_span"": 192, ""end_span"": 197, ""type"": ""Protein""}, {""token"": ""ACTB"", ""start_span"": 204, ""end_span"": 208, ""type"": ""Protein""}]"	valid
To evaluate the responsiveness of RA CD4 + T cells to IL - 10, purified PB CD4 + T cells from three patients with active RA and from three healthy controls were stimulated by immobilized anti - CD3 antibody and anti - CD28 antibody with or without diluted concentrations of IL - 10 for 36 hours, and IFN - gamma production was measured by ELISA.	CD4,37,40,Protein	IL - 10,54,61,Protein	CD4,75,78,Protein	CD3,194,197,Protein	CD28,218,222,Protein	IL - 10,274,281,Protein	IFN - gamma,300,311,Protein	"[{""token"": ""CD4"", ""start_span"": 37, ""end_span"": 40, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 54, ""end_span"": 61, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 75, ""end_span"": 78, ""type"": ""Protein""}, {""token"": ""CD3"", ""start_span"": 194, ""end_span"": 197, ""type"": ""Protein""}, {""token"": ""CD28"", ""start_span"": 218, ""end_span"": 222, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 274, ""end_span"": 281, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 300, ""end_span"": 311, ""type"": ""Protein""}]"	test
Serum IL - 6 from RA patients induces STAT3 but not STAT1 phosphorylation in normal CD4 + T cells, and exogenous IL - 6 induces the resistance to IL - 10 inhibition of IFN - gamma production.	IL - 6,6,12,Protein	STAT3,38,43,Protein	STAT1,52,57,Protein	CD4,84,87,Protein	IL - 6,113,119,Protein	IL - 10,146,153,Protein	IFN - gamma,168,179,Protein	"[{""token"": ""IL - 6"", ""start_span"": 6, ""end_span"": 12, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 38, ""end_span"": 43, ""type"": ""Protein""}, {""token"": ""STAT1"", ""start_span"": 52, ""end_span"": 57, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 84, ""end_span"": 87, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 113, ""end_span"": 119, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 146, ""end_span"": 153, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 168, ""end_span"": 179, ""type"": ""Protein""}]"	test
However, a series of studies demonstrated paucity of T cell - derived cytokines such as IL - 2 and interferon - gamma in the joints of RA, whereas macrophage and fibroblast cytokines including IL - 1, IL - 6, IL - 15, IL - 18 and TNF - alpha were abundant in rheumatoid synovium.	IL - 2,88,94,Protein	interferon - gamma,99,117,Protein	IL - 1,193,199,Protein	IL - 6,201,207,Protein	IL - 15,209,216,Protein	IL - 18,218,225,Protein	TNF - alpha,230,241,Protein	"[{""token"": ""IL - 2"", ""start_span"": 88, ""end_span"": 94, ""type"": ""Protein""}, {""token"": ""interferon - gamma"", ""start_span"": 99, ""end_span"": 117, ""type"": ""Protein""}, {""token"": ""IL - 1"", ""start_span"": 193, ""end_span"": 199, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 201, ""end_span"": 207, ""type"": ""Protein""}, {""token"": ""IL - 15"", ""start_span"": 209, ""end_span"": 216, ""type"": ""Protein""}, {""token"": ""IL - 18"", ""start_span"": 218, ""end_span"": 225, ""type"": ""Protein""}, {""token"": ""TNF - alpha"", ""start_span"": 230, ""end_span"": 241, ""type"": ""Protein""}]"	test
We detected an increase in IL - 17 level after stimulation with IL - 15 ( 10 ng / ml), whereas with IL - 1beta ( 10 ng / ml), TNF - alpha ( 10 ng / ml), IL - 18 ( 10 ng / ml) or TGF - beta ( 10 ng / ml) the levels in IL - 17 were unchanged ( Fig. 2a).	IL - 17,27,34,Protein	IL - 15,64,71,Protein	IL - 1beta,100,110,Protein	TNF - alpha,126,137,Protein	IL - 18,153,160,Protein	TGF - beta,178,188,Protein	IL - 17,217,224,Protein	"[{""token"": ""IL - 17"", ""start_span"": 27, ""end_span"": 34, ""type"": ""Protein""}, {""token"": ""IL - 15"", ""start_span"": 64, ""end_span"": 71, ""type"": ""Protein""}, {""token"": ""IL - 1beta"", ""start_span"": 100, ""end_span"": 110, ""type"": ""Protein""}, {""token"": ""TNF - alpha"", ""start_span"": 126, ""end_span"": 137, ""type"": ""Protein""}, {""token"": ""IL - 18"", ""start_span"": 153, ""end_span"": 160, ""type"": ""Protein""}, {""token"": ""TGF - beta"", ""start_span"": 178, ""end_span"": 188, ""type"": ""Protein""}, {""token"": ""IL - 17"", ""start_span"": 217, ""end_span"": 224, ""type"": ""Protein""}]"	test
Binding activities of NFkappaB, NFIL - 6 and NFAT from human PBMC to the TNFalpha, IL - 6 and IFNgamma promoters following an in vitro stimulation ( 1 h) with LPS, TSST - 1, GP, GP + LPS and GP + TSST - 1	NFIL - 6,32,40,Protein	NFAT,45,49,Protein	TNFalpha,73,81,Protein	IL - 6,83,89,Protein	IFNgamma,94,102,Protein	TSST - 1,164,172,Protein	TSST - 1,196,204,Protein	"[{""token"": ""NFIL - 6"", ""start_span"": 32, ""end_span"": 40, ""type"": ""Protein""}, {""token"": ""NFAT"", ""start_span"": 45, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 73, ""end_span"": 81, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 83, ""end_span"": 89, ""type"": ""Protein""}, {""token"": ""IFNgamma"", ""start_span"": 94, ""end_span"": 102, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 164, ""end_span"": 172, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 196, ""end_span"": 204, ""type"": ""Protein""}]"	test
Our data indicated that GP leads to production of IL - 1RA primarily via induction of NFATP2 / 3 and NFIL - 6 DNA binding, which might be due to differences in the binding motif or the composition of the activated transcription factors ( NFAT) between the IFNgamma, IL - 6 and IL - 1RA promoter.	NFATP2,86,92,Protein	3,95,96,Protein	NFIL - 6,101,109,Protein	NFAT,238,242,Protein	IFNgamma,256,264,Protein	IL - 6,266,272,Protein	IL - 1RA,277,285,Protein	"[{""token"": ""NFATP2"", ""start_span"": 86, ""end_span"": 92, ""type"": ""Protein""}, {""token"": ""3"", ""start_span"": 95, ""end_span"": 96, ""type"": ""Protein""}, {""token"": ""NFIL - 6"", ""start_span"": 101, ""end_span"": 109, ""type"": ""Protein""}, {""token"": ""NFAT"", ""start_span"": 238, ""end_span"": 242, ""type"": ""Protein""}, {""token"": ""IFNgamma"", ""start_span"": 256, ""end_span"": 264, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 266, ""end_span"": 272, ""type"": ""Protein""}, {""token"": ""IL - 1RA"", ""start_span"": 277, ""end_span"": 285, ""type"": ""Protein""}]"	test
IFNgamma, TNFalpha, IL - 1 and IL - 6 were determined using an ELISA from Bender Systems ( Vienna, Austria), IL - 1RA and IL - 8 by an ELISA from R & D Systems ( Wiesbaden - Nordenstadt, Germany), and TGFbeta 1 using an ELISA as previously described [ 57].	IFNgamma,0,8,Protein	TNFalpha,10,18,Protein	IL - 1,20,26,Protein	IL - 6,31,37,Protein	IL - 1RA,109,117,Protein	IL - 8,122,128,Protein	TGFbeta 1,201,210,Protein	"[{""token"": ""IFNgamma"", ""start_span"": 0, ""end_span"": 8, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 10, ""end_span"": 18, ""type"": ""Protein""}, {""token"": ""IL - 1"", ""start_span"": 20, ""end_span"": 26, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 31, ""end_span"": 37, ""type"": ""Protein""}, {""token"": ""IL - 1RA"", ""start_span"": 109, ""end_span"": 117, ""type"": ""Protein""}, {""token"": ""IL - 8"", ""start_span"": 122, ""end_span"": 128, ""type"": ""Protein""}, {""token"": ""TGFbeta 1"", ""start_span"": 201, ""end_span"": 210, ""type"": ""Protein""}]"	test
Nuclear extracts were incubated with a 32P - labeled NFAT, NFkappaB, NFIL - 6 or NFkappaB - IL - 8 oligonucleotide probe corresponding to the IFNgamma, TNFalpha, IL - 6 and IL - 8 gene promoters ( Table 1).	NFAT,53,57,Protein	NFIL - 6,69,77,Protein	IL - 8,92,98,Protein	IFNgamma,142,150,Protein	TNFalpha,152,160,Protein	IL - 6,162,168,Protein	IL - 8,173,179,Protein	"[{""token"": ""NFAT"", ""start_span"": 53, ""end_span"": 57, ""type"": ""Protein""}, {""token"": ""NFIL - 6"", ""start_span"": 69, ""end_span"": 77, ""type"": ""Protein""}, {""token"": ""IL - 8"", ""start_span"": 92, ""end_span"": 98, ""type"": ""Protein""}, {""token"": ""IFNgamma"", ""start_span"": 142, ""end_span"": 150, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 152, ""end_span"": 160, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 162, ""end_span"": 168, ""type"": ""Protein""}, {""token"": ""IL - 8"", ""start_span"": 173, ""end_span"": 179, ""type"": ""Protein""}]"	test
The IKK complex is comprised of the two catalytic subunits IKK1 and IKK2 ( also known as IKKalpha and IKKbeta) and the regulatory subunit NF - kappaB essential modulator ( NEMO - also known as IKKgamma) ( Figure 1).	IKK1,59,63,Protein	IKK2,68,72,Protein	IKKalpha,89,97,Protein	IKKbeta,102,109,Protein	NF - kappaB essential modulator,138,169,Protein	NEMO,172,176,Protein	IKKgamma,193,201,Protein	"[{""token"": ""IKK1"", ""start_span"": 59, ""end_span"": 63, ""type"": ""Protein""}, {""token"": ""IKK2"", ""start_span"": 68, ""end_span"": 72, ""type"": ""Protein""}, {""token"": ""IKKalpha"", ""start_span"": 89, ""end_span"": 97, ""type"": ""Protein""}, {""token"": ""IKKbeta"", ""start_span"": 102, ""end_span"": 109, ""type"": ""Protein""}, {""token"": ""NF - kappaB essential modulator"", ""start_span"": 138, ""end_span"": 169, ""type"": ""Protein""}, {""token"": ""NEMO"", ""start_span"": 172, ""end_span"": 176, ""type"": ""Protein""}, {""token"": ""IKKgamma"", ""start_span"": 193, ""end_span"": 201, ""type"": ""Protein""}]"	test
TNF stimulation results in the recruitment of TNF receptor - 1 - associated death domain ( TRADD) protein and of receptor interacting protein 1 ( RIP1), which function as adaptor proteins for the E3 ubiquitin ligases TNF receptor - associated factor ( TRAF) 2 and TRAF5, which in turn bind the E3 ubiquitin ligases cellular inhibitor of apoptosis ( cIAP) 1 and cIAP2 ( Figure 1).	TNF,0,3,Protein	TNF receptor - 1 - associated death domain,46,88,Protein	TRADD,91,96,Protein	receptor interacting protein 1,113,143,Protein	RIP1,146,150,Protein	TRAF5,264,269,Protein	cIAP2,361,366,Protein	"[{""token"": ""TNF"", ""start_span"": 0, ""end_span"": 3, ""type"": ""Protein""}, {""token"": ""TNF receptor - 1 - associated death domain"", ""start_span"": 46, ""end_span"": 88, ""type"": ""Protein""}, {""token"": ""TRADD"", ""start_span"": 91, ""end_span"": 96, ""type"": ""Protein""}, {""token"": ""receptor interacting protein 1"", ""start_span"": 113, ""end_span"": 143, ""type"": ""Protein""}, {""token"": ""RIP1"", ""start_span"": 146, ""end_span"": 150, ""type"": ""Protein""}, {""token"": ""TRAF5"", ""start_span"": 264, ""end_span"": 269, ""type"": ""Protein""}, {""token"": ""cIAP2"", ""start_span"": 361, ""end_span"": 366, ""type"": ""Protein""}]"	test
Recently, the disruption of interactions between E2 ubiquitin conjugating enzymes ( Ubc13 and Ubc5hc) and E3 ubiquitin ligases ( TRAF6, TRAF2 and cIAP1 / 2) were described as another important mechanism used by A20 to downregulate NF - kappaB signalling [ 42].	Ubc13,84,89,Protein	Ubc5hc,94,100,Protein	TRAF6,129,134,Protein	TRAF2,136,141,Protein	cIAP1,146,151,Protein	2,154,155,Protein	A20,211,214,Protein	"[{""token"": ""Ubc13"", ""start_span"": 84, ""end_span"": 89, ""type"": ""Protein""}, {""token"": ""Ubc5hc"", ""start_span"": 94, ""end_span"": 100, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 129, ""end_span"": 134, ""type"": ""Protein""}, {""token"": ""TRAF2"", ""start_span"": 136, ""end_span"": 141, ""type"": ""Protein""}, {""token"": ""cIAP1"", ""start_span"": 146, ""end_span"": 151, ""type"": ""Protein""}, {""token"": ""2"", ""start_span"": 154, ""end_span"": 155, ""type"": ""Protein""}, {""token"": ""A20"", ""start_span"": 211, ""end_span"": 214, ""type"": ""Protein""}]"	test
A20 expression in synovial tissue was associated with inhibition of NF - kappaB activity and decreased levels of TNF, IL - 1beta, IL - 6, soluble RANKL, monocyte chemo - attractant protein 1, and IL - 17, suggesting that A20 induces a protective effect in collagen - induced arthritis mice through suppression of NF - kappaB activation and NF - kappaB - dependent gene expression [ 51].	A20,0,3,Protein	TNF,113,116,Protein	IL - 1beta,118,128,Protein	IL - 6,130,136,Protein	RANKL,146,151,Protein	monocyte chemo - attractant protein 1,153,190,Protein	A20,221,224,Protein	"[{""token"": ""A20"", ""start_span"": 0, ""end_span"": 3, ""type"": ""Protein""}, {""token"": ""TNF"", ""start_span"": 113, ""end_span"": 116, ""type"": ""Protein""}, {""token"": ""IL - 1beta"", ""start_span"": 118, ""end_span"": 128, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 130, ""end_span"": 136, ""type"": ""Protein""}, {""token"": ""RANKL"", ""start_span"": 146, ""end_span"": 151, ""type"": ""Protein""}, {""token"": ""monocyte chemo - attractant protein 1"", ""start_span"": 153, ""end_span"": 190, ""type"": ""Protein""}, {""token"": ""A20"", ""start_span"": 221, ""end_span"": 224, ""type"": ""Protein""}]"	test
Single - immunoglobulin IL - 1 receptor - related ( SIGIRR) protein, also known as TIR - 8, is a member of the TLR / IL - 1R family that has been extensively characterised as an inhibitor of IL - 1R and TLR signalling, probably through direct interaction with these receptors, MyD88, IRAK1 or TRAF6 [ 67] ( Figure 1).	Single - immunoglobulin IL - 1 receptor - related,0,49,Protein	SIGIRR,52,58,Protein	TIR - 8,83,90,Protein	IL - 1R,117,124,Protein	MyD88,277,282,Protein	IRAK1,284,289,Protein	TRAF6,293,298,Protein	"[{""token"": ""Single - immunoglobulin IL - 1 receptor - related"", ""start_span"": 0, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""SIGIRR"", ""start_span"": 52, ""end_span"": 58, ""type"": ""Protein""}, {""token"": ""TIR - 8"", ""start_span"": 83, ""end_span"": 90, ""type"": ""Protein""}, {""token"": ""IL - 1R"", ""start_span"": 117, ""end_span"": 124, ""type"": ""Protein""}, {""token"": ""MyD88"", ""start_span"": 277, ""end_span"": 282, ""type"": ""Protein""}, {""token"": ""IRAK1"", ""start_span"": 284, ""end_span"": 289, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 293, ""end_span"": 298, ""type"": ""Protein""}]"	test
In unstimulated cells NIK forms a cytosolic complex with the ubiquitin ligases TRAF2, TRAF3 and cIAP1 / 2, which facilitates the K48 - linked polyubiquitination and proteasomal degradation of NIK, keeping NIK levels low.	NIK,22,25,Protein	TRAF2,79,84,Protein	TRAF3,86,91,Protein	cIAP1,96,101,Protein	2,104,105,Protein	NIK,192,195,Protein	NIK,205,208,Protein	"[{""token"": ""NIK"", ""start_span"": 22, ""end_span"": 25, ""type"": ""Protein""}, {""token"": ""TRAF2"", ""start_span"": 79, ""end_span"": 84, ""type"": ""Protein""}, {""token"": ""TRAF3"", ""start_span"": 86, ""end_span"": 91, ""type"": ""Protein""}, {""token"": ""cIAP1"", ""start_span"": 96, ""end_span"": 101, ""type"": ""Protein""}, {""token"": ""2"", ""start_span"": 104, ""end_span"": 105, ""type"": ""Protein""}, {""token"": ""NIK"", ""start_span"": 192, ""end_span"": 195, ""type"": ""Protein""}, {""token"": ""NIK"", ""start_span"": 205, ""end_span"": 208, ""type"": ""Protein""}]"	test
Cells were stained with monoclonal antibodies directed against MHC - II ( I - A / I - E) FITC ( M5 / 114. 15. 2), CD11c PerCP - Cy5. 5 ( N418), F4 / 80 APC ( BM8), CD62L PE ( MEL - 14), Granzyme B FITC ( NGZB) from eBiosciences and CD3 Molecular Complex Horizon v450 ( 17A2), Ly6C Horizon v450 ( AL - 21), Ly6G PE ( 1A8), CD11b APC - Cy7 ( M1 / 70), CD8alpha PerCP ( 53 - 6. 7), IFNgamma Alexa 647 ( XMG1. 2) and CD16 / 32 ( 2. 4G2) from BD Pharmingen.	CD62L,164,169,Protein	Granzyme B,186,196,Protein	CD3,232,235,Protein	Ly6G,306,310,Protein	CD8alpha,350,358,Protein	IFNgamma,379,387,Protein	CD16,413,417,Protein	"[{""token"": ""CD62L"", ""start_span"": 164, ""end_span"": 169, ""type"": ""Protein""}, {""token"": ""Granzyme B"", ""start_span"": 186, ""end_span"": 196, ""type"": ""Protein""}, {""token"": ""CD3"", ""start_span"": 232, ""end_span"": 235, ""type"": ""Protein""}, {""token"": ""Ly6G"", ""start_span"": 306, ""end_span"": 310, ""type"": ""Protein""}, {""token"": ""CD8alpha"", ""start_span"": 350, ""end_span"": 358, ""type"": ""Protein""}, {""token"": ""IFNgamma"", ""start_span"": 379, ""end_span"": 387, ""type"": ""Protein""}, {""token"": ""CD16"", ""start_span"": 413, ""end_span"": 417, ""type"": ""Protein""}]"	test
TNF - alpha shows various effects on brain function depending on its local tissue concentration, the type of target cells, and especially the specific receptor subtype: TNF receptor I, or p55 receptor ( TNFp55R); and TNF receptor II, or p75 receptor ( TNFp75R) [ 19].	TNF - alpha,0,11,Protein	TNF receptor I,169,183,Protein	p55 receptor,188,200,Protein	TNFp55R,203,210,Protein	TNF receptor II,217,232,Protein	p75 receptor,237,249,Protein	TNFp75R,252,259,Protein	"[{""token"": ""TNF - alpha"", ""start_span"": 0, ""end_span"": 11, ""type"": ""Protein""}, {""token"": ""TNF receptor I"", ""start_span"": 169, ""end_span"": 183, ""type"": ""Protein""}, {""token"": ""p55 receptor"", ""start_span"": 188, ""end_span"": 200, ""type"": ""Protein""}, {""token"": ""TNFp55R"", ""start_span"": 203, ""end_span"": 210, ""type"": ""Protein""}, {""token"": ""TNF receptor II"", ""start_span"": 217, ""end_span"": 232, ""type"": ""Protein""}, {""token"": ""p75 receptor"", ""start_span"": 237, ""end_span"": 249, ""type"": ""Protein""}, {""token"": ""TNFp75R"", ""start_span"": 252, ""end_span"": 259, ""type"": ""Protein""}]"	test
To determine the specificity of these substitutions upon NFAT5 and NF - kappaB p50 / p65 binding to the LTR, we performed a quantitative DNase I footprinting analysis using the wild - type LTR or mutant LTRs in combination with increasing concentrations of recombinant NFAT5 or NF - kappaB p50 / p65 proteins.	NFAT5,57,62,Protein	p50,79,82,Protein	p65,85,88,Protein	DNase I,137,144,Protein	NFAT5,269,274,Protein	p50,290,293,Protein	p65,296,299,Protein	"[{""token"": ""NFAT5"", ""start_span"": 57, ""end_span"": 62, ""type"": ""Protein""}, {""token"": ""p50"", ""start_span"": 79, ""end_span"": 82, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 85, ""end_span"": 88, ""type"": ""Protein""}, {""token"": ""DNase I"", ""start_span"": 137, ""end_span"": 144, ""type"": ""Protein""}, {""token"": ""NFAT5"", ""start_span"": 269, ""end_span"": 274, ""type"": ""Protein""}, {""token"": ""p50"", ""start_span"": 290, ""end_span"": 293, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 296, ""end_span"": 299, ""type"": ""Protein""}]"	test
Quantitative DNaseI footprinting analysis is shown of nucleotides - 262 to + 4 from HIV - 1Lai / Bal - env - WT, HIV - 1Lai / Bal - env - kappaB I - Mut, HIV - 1Lai / Bal - env - kappaB II - Mut, and HIV - 1Lai / Bal - env - kappaB I + II - Mut and increasing concentrations of recombinant NF - kappaB ( p50 / p65) ( 25 ng, 100 ng, and 500 ng).	DNaseI,13,19,Protein	env,103,106,Protein	env,132,135,Protein	env,173,176,Protein	env,219,222,Protein	p50,304,307,Protein	p65,310,313,Protein	"[{""token"": ""DNaseI"", ""start_span"": 13, ""end_span"": 19, ""type"": ""Protein""}, {""token"": ""env"", ""start_span"": 103, ""end_span"": 106, ""type"": ""Protein""}, {""token"": ""env"", ""start_span"": 132, ""end_span"": 135, ""type"": ""Protein""}, {""token"": ""env"", ""start_span"": 173, ""end_span"": 176, ""type"": ""Protein""}, {""token"": ""env"", ""start_span"": 219, ""end_span"": 222, ""type"": ""Protein""}, {""token"": ""p50"", ""start_span"": 304, ""end_span"": 307, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 310, ""end_span"": 313, ""type"": ""Protein""}]"	test
Expression of the C / EBP - beta phospho - acceptor mutant, C / EBPbetaT217A, in Cebpb - / - MEFs did not significantly increase SerpinB2 promoter activity above that of wild - type C / EBP - beta ( Fig. 8C, right); confirming that phosphorylation of C / EBP - beta at T217 is not a major factor in the regulation of SerpinB2 promoter activity in response to LPS.	C / EBP - beta phospho - acceptor mutant,18,58,Protein	C / EBPbetaT217A,60,76,Protein	Cebpb,81,86,Protein	SerpinB2,129,137,Protein	C / EBP - beta,182,196,Protein	C / EBP - beta,251,265,Protein	SerpinB2,317,325,Protein	"[{""token"": ""C / EBP - beta phospho - acceptor mutant"", ""start_span"": 18, ""end_span"": 58, ""type"": ""Protein""}, {""token"": ""C / EBPbetaT217A"", ""start_span"": 60, ""end_span"": 76, ""type"": ""Protein""}, {""token"": ""Cebpb"", ""start_span"": 81, ""end_span"": 86, ""type"": ""Protein""}, {""token"": ""SerpinB2"", ""start_span"": 129, ""end_span"": 137, ""type"": ""Protein""}, {""token"": ""C / EBP - beta"", ""start_span"": 182, ""end_span"": 196, ""type"": ""Protein""}, {""token"": ""C / EBP - beta"", ""start_span"": 251, ""end_span"": 265, ""type"": ""Protein""}, {""token"": ""SerpinB2"", ""start_span"": 317, ""end_span"": 325, ""type"": ""Protein""}]"	test
